Drug Search Results
More Filters [+]

BIIB-022

Alternative Names: biib-022, biib022, biib 022
Latest Update: 2017-01-09
Latest Update Note: Clinical Trial Update

Product Description

BIIB022 is a non-glycosylated human IgG4 monoclonal antibody (mAb) with specificity for IGF-1R.

Mechanisms of Action: IGF Blocker

Novel Mechanism: Yes

Modality: Antibody

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Biogen
Company Location: CAMBRIDGE MA 02142
Company CEO: Michel Vounatsos
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for BIIB-022

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Hepatocellular Carcinoma|Oncology Solid Tumor Unspecified|Non-Small-Cell Lung Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

212-LC-101

P1

Completed

Non-Small-Cell Lung Cancer

2011-09-01

212HC201

P1

Completed

Hepatocellular Carcinoma

2011-04-01

212ST101

P1

Completed

Oncology Solid Tumor Unspecified

2010-04-01

Recent News Events

Date

Type

Title